General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Annual results

Annual Results 2010 - Jan 27, 2011

2010
(USD m)
2009
(USD m)
% change
(USD)
Net sales 50,624 44,267 14
Operating income 11,526 9,982 15
Net income 9,969 8,454 18
Basic EPS (USD)1 USD 4.28 USD 3.70 16
Core2
Operating income 14,006 11,437 22
Net income 12,029 10,267 17
Basic EPS (USD) USD 5.15 USD 4.50 14
  1. 2010 average number of shares outstanding: 2 285.7 million (2009: 2 267.9 million).
  2. Core results for operating income, net income and earnings per share (EPS) eliminate the impact of acquisition-related factors and other significant exceptional items.


Media release

The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Stock chart